Key Highlights
- Dr. Patrick Soon-Shiong joins Avenacy as co-founder and board member.
- NantCapital’s funding to propel Avenacy’s growth and portfolio expansion.
- Avenacy has launched 11 injectable products to address critical U.S. drug shortages.
- Partnership leverages a seasoned management team and global network.
Source: Business Wire
Notable Quotes
- “As a medical professional, I care deeply about ensuring patients receive safe, high-quality medications, and I standby Avenacy’s commitment to patient care.” — Dr. Patrick Soon-Shiong, Co-founder at Avenacy
- “We are thrilled to have the support of esteemed pharmaceutical investor and businessman, Dr. Patrick Soon-Shiong.” — Jeff Yordon, Co-founder and CEO at Avenacy
SoHC's Take
Avenacy’s strategic move to bring Dr. Patrick Soon-Shiong on board as a co-founder signals a significant step forward for the company in addressing the critical shortages of injectable medications in the U.S. market. With Soon-Shiong’s extensive track record and NantCapital’s backing, Avenacy is well-positioned to expand its portfolio and cement its reputation as a key player in the specialty pharmaceutical industry. The combined leadership of Soon-Shiong and Yordon, both of whom have a history of building successful pharmaceutical ventures, bodes well for Avenacy’s future growth and its mission to deliver safe, high-quality medications to healthcare providers nationwide.
